Financial Summary
Able Laboratories, Inc., through its subsidiaries, Superior Pharmaceutical Company, Generic Distributors, Inc. and
Apex Pharmaceuticals, develops, manufactures and distributes generic pharmaceuticals. For the three months ended
3/31/01, revenues fell 52% to $3.9 million. Net loss applicable to Common totaled $3.3 million, up from $583
thousand. Revenues reflect the sales of distribution subsidiaries. Net loss reflects a $1.8 million preferred stock
conversion charge.
Per-Share Data
Book Value (mrq)
$0.02
Earnings (ttm)
-$0.14
Earnings (mrq)
-$0.03
Sales (ttm)
$0.31
Cash (mrq)
$0.00
Share-Related Items
Market Capitalization
$28.5M
Shares Outstanding
114.0M
Float
95.8M
Income Statements
Sales (ttm)
$27.3M
EBITDA (ttm)
-$5.57M
Income available to common (ttm)
-$12.6M
==================================================================================
Friday July 13, 8:23 am Eastern Time
Press Release
Able Laboratories Receives FDA Approval for Prochlorperazine Suppositories
USP, 2.5 Mg, 5 Mg and 25 Mg
-- The Only Company to Offer Generic Version of Compazine® in All Three Strengths --
biz.yahoo.com
==================================================================================
Thursday July 12, 8:45 am Eastern Time
Press Release
Able Laboratories Receives FDA Approval for Propoxyphene Napsylate and
Acetaminophen 100 Mg and 650 Mg Tablets
Generic Version of Darvocet-N® With Estimated Generic Market of $450 Million
biz.yahoo.com
==================================================================================
Tom B. |
